Radius Health, Inc. (NASDAQ:RDUS)‘s stock had its “hold” rating restated by Jefferies Group LLC in a research report issued on Wednesday, August 9th. They currently have a $38.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $34.00. Jefferies Group LLC’s target price suggests a potential upside of 6.98% from the stock’s current price.
Several other research analysts also recently commented on RDUS. Zacks Investment Research downgraded Radius Health from a “hold” rating to a “sell” rating in a research report on Wednesday, April 26th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $65.00 price target on shares of Radius Health in a research report on Friday, April 28th. Canaccord Genuity reaffirmed a “buy” rating on shares of Radius Health in a research report on Friday, April 28th. Maxim Group reaffirmed a “sell” rating on shares of Radius Health in a research report on Monday, May 1st. Finally, Cowen and Company downgraded Radius Health from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 2nd. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $53.60.
Radius Health (NASDAQ:RDUS) traded up 0.28% during mid-day trading on Wednesday, reaching $35.52. 539,938 shares of the company were exchanged. The stock’s 50-day moving average is $41.97 and its 200-day moving average is $40.13. The company’s market cap is $1.55 billion. Radius Health has a 12 month low of $31.58 and a 12 month high of $59.22.
Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by $0.23. The company had revenue of $0.98 million during the quarter, compared to analysts’ expectations of $1.96 million. During the same period in the prior year, the business posted ($1.01) EPS. Equities analysts expect that Radius Health will post ($5.51) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This story was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.com-unik.info/2017/08/19/radius-health-inc-rdus-earns-hold-rating-from-jefferies-group-llc-updated.html.
In other news, major shareholder Growth N. V. Biotech acquired 150,000 shares of the stock in a transaction dated Thursday, August 10th. The shares were acquired at an average cost of $34.97 per share, for a total transaction of $5,245,500.00. Following the completion of the transaction, the insider now owns 5,113,799 shares in the company, valued at approximately $178,829,551.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Growth N. V. Biotech acquired 40,000 shares of the stock in a transaction dated Tuesday, May 30th. The shares were purchased at an average price of $34.21 per share, for a total transaction of $1,368,400.00. Following the completion of the transaction, the insider now owns 5,038,799 shares of the company’s stock, valued at approximately $172,377,313.79. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 290,000 shares of company stock worth $10,222,700. 15.00% of the stock is currently owned by company insiders.
Several hedge funds have recently added to or reduced their stakes in RDUS. BB Biotech AG boosted its stake in Radius Health by 11.0% in the second quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock worth $227,905,000 after buying an additional 498,400 shares in the last quarter. Farallon Capital Management LLC raised its stake in shares of Radius Health by 18.3% in the second quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock valued at $166,731,000 after buying an additional 569,300 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Radius Health by 4.5% in the second quarter. Vanguard Group Inc. now owns 3,145,717 shares of the biopharmaceutical company’s stock valued at $142,281,000 after buying an additional 135,071 shares in the last quarter. BlackRock Inc. raised its stake in shares of Radius Health by 10.0% in the second quarter. BlackRock Inc. now owns 2,893,641 shares of the biopharmaceutical company’s stock valued at $130,881,000 after buying an additional 262,896 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Radius Health by 12.9% in the second quarter. State Street Corp now owns 1,867,531 shares of the biopharmaceutical company’s stock valued at $84,473,000 after buying an additional 213,399 shares in the last quarter. Institutional investors and hedge funds own 97.66% of the company’s stock.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
What are top analysts saying about Radius Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Radius Health Inc. and related companies.